Bu-Fei Yi-Shen Granules Reduce Acute Exacerbations in Patients with GOLD 3-4 COPD: A Randomized Controlled Trial.
Xue-Qing YuJia-Qi DiWei ZhangGeng-Shu WeiZhan-Ping MaLei WuXue-Feng YuHui-Zhi ZhuMiao ZhouCui-Ling FengJi-Hong FengPing FanJian-Sheng LiJian-Ya YangPublished in: International journal of chronic obstructive pulmonary disease (2023)
BYG, as compared to a placebo, could significantly reduce the frequencies of AEs and AE-related hospitalizations for GOLD 3-4 COPD patients. Clinical symptoms, treatment satisfaction, quality of life, and exercise capacity improved. There was no significant improvement in mortality and pulmonary function.
Keyphrases
- chronic obstructive pulmonary disease
- end stage renal disease
- lung function
- newly diagnosed
- ejection fraction
- cystic fibrosis
- chronic kidney disease
- liver failure
- prognostic factors
- physical activity
- clinical trial
- randomized controlled trial
- drug induced
- coronary artery disease
- cardiovascular disease
- sleep quality
- open label
- replacement therapy
- placebo controlled